Introduction
Sweet's syndrome is an acute febrile neutrophilic dermatosis typically characterized by the sudden onset of pyrexia, increased number or percent of neutrophils, and painful red skin lesions that consist of a diffuse dermal infiltrate of neutrophils; in addition, the symptoms and lesions promptly respond to systemic corticosteroids [1] . The condition can occur in an idiopathic setting, most commonly in young women associated with a streptococcal pharyngitis [2] .
Alternatively, its onset can be associated with either other conditions-such as pregnancy, inflammatory bowel disease or cancer-or drugs [3] . A woman with recurrent breast cancer who developed her first episode of Sweet's syndrome after an initial exposure to omeprazole and a recurrence of the dermatosis immediately after receiving a single dose of esomeprazole is described. A clinical diagnosis of gastroesophageal reflux disease was made and she was started on 20 mg of omeprazole daily.
Case report
Within 6 days, she developed severe neck pain; 2 days later she had "blisters on her palms." She was evaluated in the emergency department 8 days after initiating omeprazole; the medication was stopped and she received dilaudid (and subsequently ibuprofen) for her neck pain and ondansetron 4 mg every 8 hours, as needed, for her nausea. The next day her primary care physician prescribed prednisone (40 mg daily for 5 days) for the painful blisters on her hands.
She returned for evaluation after completing the prednisone. Her neck pain had improved and the lesions on her hands had resolved. However, her gastrointestinal symptoms persisted. The ondansetron was stopped and her primary care physician prescribed 20 mg of esomeprazole daily.
Within 6 hours after she took her first dose of esomeprazole, the neck pain returned and the skin lesions on her cancer patients-either in a paraneoplastic setting [7] [8] [9] [10] [11] [12] [13] [14] or as an incidental dermatosis occurring in the individual's lymphedematous arm following ipsilateral mastectomy and lymph node dissection [15] [16] [17] [18] [19] [20] . The currently described woman had an established diagnosis of metastatic breast cancer that had been treated; she had achieved a clinical remission. However, the development of Sweet's syndrome and persistent symptoms suggestive of gastroesophageal reflux disease prompted additional investigation that discovered biopsy-confirmed recurrence of her breast cancer presenting with metastasis to the gastric mucosa [21] [22] [23] [24] [25] .
Diagnostic criteria for drug-induced Sweet's syndrome were introduced in 1996 [26] . Subsequently, an increasing number of medications have been associated with the development of Sweet's syndrome [27] . Granulocyte colony stimulating factor is the most frequently described agent to elicit the dermatosis; as expected, this usually occurs in patients with new or recurrent malignancy who are being treated with antineoplastic therapy and receive the granulocyte colony stimulating factor for treatment-related neutropenia [1, 14] .
The proton pump is a term that refers to the gastric parietal cell H+-K+-adenosine triphosphatase (ATPase); proton pump inhibitors selectively inhibit this enzyme and thereby inhibit gastric acid secretion [28, 29] . Agents in this class of drugs include dexlansoprozole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, and tenatoprazole [29, 30] . The drugs are primarily used to treat gastroesophageal reflux disease in children and adults [31, 32] .
Cutaneous adverse reactions to proton pump inhibitors are uncommon [33] . A retrospective study performed in Thailand discovered a prevalence of skin reactions ranging from three to 20 per 100,000 of the treated population. A "maculopapular rash" was the most frequently observed proton pump inhibitor-induced skin reaction [34] .
Proton pump inhibitor-associated subacute cutaneous lupus erythematosus was initially described in 2005 and its recognition is increasing [35] . A recently published retrospective series of 24 patients from Denmark noted the skin rash was widespread with a tendency to bullous lesions and focal skin necrosis and that most individuals had anti-Ro/Sjogren syndrome A antibodies. Twelve and a half percent (3/24) of the patients who developed drug-induced subacute cutaneous lupus erythematosus reacted to more than one proton pump inhibitor, similar to the described patient [36] .
Life threatening dermatoses secondary to proton pump inhibitors have also been described, albeit rarely [30, 37, 38] .
To the best of my knowledge, proton pump inhibitor-induced Sweet's syndrome has not previously been observed. The currently reported woman had never previously been exposed to proton pump inhibitors; she experienced her initial episode of Sweet's syndrome 8 days after starting omeprazole and chemistry stains showed that the tumor cells were positive for BRST-2-a monoclonal antibody that detects gross cystic dis- Sweet's syndrome in oncology patients can be idiopathic or related to a medication they are receiving either to treat the cancer or to manage a drug-induced neutropenia and/or associated with the discovery of a previously undiagnosed malignancy or recurrence of an established neoplasm [5] . Paraneoplastic Sweet's syndrome is most commonly observed in patients with acute myelogenous leukemia [6] .
Solid tumor-associated Sweet' syndrome has most frequently been described in patients with carcinomas of the genitourinary organs, breast, and gastrointestinal tract [7] .
However, Sweet's syndrome has also been described in breast Naranjo et al developed a method for estimating the probability of adverse drug reactions [39] . They not only created and studied an adverse drug reaction probability scale (Table 1 ), but also found that their scale was reliable and valid for: (1) assessing a potential adverse drug reaction and (2) assigning a probability category. According to Naranjo et al's adverse drug probability scale, Sweet's syndrome developing as an adverse drug reaction induced by proton pump inhibitors would be assigned to a definite probability category in the reported patient (Table 1) .
In summary, the temporal relationship between initially receiving a proton pump inhibitor and the onset of Sweet's [c] An answer of "Do not know" = 0 score.
[d] From the total score, the adverse drug reaction is assigned a probability category: definite (greater than or equal to 9), probable (5 to 8), possible (1 to 4), doubtful (less than or equal to 0).
[e] Drug = proton pump inhibitor: omeprazole and esomeprazole.
[f] Although the detection of recurrent breast cancer raised the possibility of paraneoplastic Sweet's syndrome, the dermatosis remained in remission: (1) after withdrawal of the proton pump inhibitor and either systemic or topical corticosteroid treatment and (2) as the patient's CA153 tumor marker increased in association with the persistence of her antineoplastic therapy-treated metastatic malignancy.
[g] The patient received oral medications for neck pain and nausea following the initial episode of Sweet's syndrome without recurrence of the dermatosis: dilaudid, ibuprofen, and ondansetron. 
